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Abstract
Background: There has been a recent upsurge of interest in complementary medicine, especially dietary supplements
and foods functional in delaying the onset of age-associated neurodegenerative diseases. Mushrooms have long been
used in traditional medicine for thousands of years, being now increasingly recognized as antitumor, antioxidant,
antiviral, antibacterial and hepatoprotective agent also capable to stimulate host immune responses.
Results: Here we provide evidence of neuroprotective action of Hericium Herinaceus when administered orally to rat.
Expression of Lipoxin A4 (LXA4) was measured in different brain regions after oral administration of a biomass Hericium
preparation, given for 3 month. LXA4 up-regulation was associated with an increased content of redox sensitive proteins
involved in cellular stress response, such as Hsp72, Heme oxygenase −1 and Thioredoxin. In the brain of rats receiving
Hericium, maximum induction of LXA4 was observed in cortex, and hippocampus followed by substantia Nigra, striatum
and cerebellum. Increasing evidence supports the notion that oxidative stress-driven neuroinflammation is a fundamental
cause in neurodegenerative diseases. As prominent intracellular redox system involved in neuroprotection, the vitagene
system is emerging as a neurohormetic potential target for novel cytoprotective interventions. Vitagenes encode
for cytoprotective heat shock proteins 70, heme oxygenase-1, thioredoxin and Lipoxin A4. Emerging interest is
now focussing on molecules capable of activating the vitagene system as novel therapeutic target to minimize
deleterious consequences associated with free radical-induced cell damage, such as in neurodegeneration. LXA4
is an emerging endogenous eicosanoid able to promote resolution of inflammation, acting as an endogenous
“braking signal” in the inflammatory process. In addition, Hsp system is emerging as key pathway for modulation
to prevent neuronal dysfunction, caused by protein misfolding.
Conclusions: Conceivably, activation of LXA4 signaling and modulation of stress responsive vitagene proteins
could serve as a potential therapeutic target for AD-related inflammation and neurodegenerative damage.
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Background
With the increased lifespan of the world’s population, it is
estimated that about 80 million people will suffer from de-
mentia by 2040 whereby AD accounted for almost 60 % of
dementia cases [1–4]. Ageing, inexorable with decline in
immune competence and onset of chronic inflammation,
is one major causative factor associated to neurodegenera-
tive diseases including dementia, Alzheimer’s disease (AD)
and Parkinson’s disease (PD); atherosclerosis and stroke;
diabetes; sarcopenia; and cancer [1–4]. Mushrooms have
been used in traditional medicine for thousands of years
[5, 6]. Many controlled studies have since investigated the
long list of medicinal actions thought to be associated with
extracts of these and other mushrooms, including antitu-
mor, immunomodulatory, antioxidant, antiviral, antibac-
terial, and hepatoprotective effects [7]. Mushrooms are a
rich source of polysaccharides and low molecular weight
peptides [8–11], and many have been shown to stimulate
host immune responses [12, 13]. The administration of
complex mixtures of molecules of unknown concentra-
tions is difficult to reconcile with current pharmaceutical
practices involving highly purified compounds. The active
ingredients may be unknown, making mushroom extracts
very difficult to patent. Moreover, mushroom‑derived
polysaccharides are complex molecules that cannot be
synthesized, as the mass production of these compounds
would require timely and costly extraction processes. As a
result, many research efforts have focused on low molecu-
lar weight compounds, such as cordycepin [14]. Of the
mushroom-derived therapeutics, polysaccharopeptides ob-
tained from Agaricus campestris, Pleurotus ostreatus and
Coriolus versicolor [15, 16], as well as Hericium erinaceus
[17] are commercially the best established. While Coriolus
versicolor is widely used to degrade recalcitrant organic pol-
lutants such as pentachlorophenol (PCP) [18], H. erinaceus,
has been used in traditional medical practices in China and
Japan as to treat various human diseases. H. erinaceus
mushroom is harvested, dried, ground, and made into me-
dicinal preparations. The compounds isolated from fruiting
bodies contain numerous biological activities, such as anti-
tumor, hypolipidemic, hemagglutinating, cytotoxic, anti-
microbial, endoplamic reticulum (ER) stress-suppressive,
and antioxidant activities. In particular, it has been reported
that hericenones and erinacines stimulate nerve growth
factor (NGF) synthesis in cultured astrocytes. Erinacines
have been isolated from cultured mycelia of H. erinaceus,
and identified as one of diterpenoids. Hericenones have
been isolated from the fruiting bodies of H. erinaceus and
its molecular formula determined. In addition, studies from
whole brain and cell cultures have shown that NGF
affects the viability of cholinergic neurons, stimulating
in the CNS the activity of enzymes, such as choline-
acetyltransferase and acetylcholinesterase. These results
are consistent with clinical finding indicating that H.
erinaceus supplementation improves mild cognitive
impairment, a condition where cholinergic neurons are
centrally involved. However, despite the clinical rele-
vance of H. erinaceus nutritional approaches, there
have been only few studies elucidating mechanisms
impacting defined brain physiopathological processes
underlying the determinism of neurodegeneration
involved in AD, as well as other types of dementia.
Recently, the involvement of neuroinflammation and
microglial activation in the pathogenesis of AD has
been emphasized by compelling evidence from basic
and clinical research studies indicating that inflamma-
tion induced by amyloid beta (Aβ) is intimately asso-
ciated with the development of AD neuropathology
[19], in a scenario where Aβ activates microglia [20],
the resident macrophages of the brain, and activated
microglia may then promote neuronal injury through
the release of proinflammatory and cytotoxic factors,
sustaining further glial activation via a detrimental
cycle where neuroinflammation and oxidative stress
act in synergy, exacerbating the course of the disease
[21]. Consistent to this notion, recent advances in
knowledge of the mechanisms of inflammatory reso-
lution have identified lipoxins as attractive therapeutic
tools to treat diseases in which inflammation is in-
volved [22]. Lipoxin (LXA4) is generated via the
lipoxygenase pathway during cell-cell interactions in
inflammatory conditions, whereas aspirin-triggered
LXA4 (ATL), a molecule that displays the same anti-
inflammatory activities as the native lipoxins, is gen-
erated after the acetylation of cyclooxygenase-2 and is
more resistant to metabolic inactivation [23]. How-
ever, the ability of LXA4 signaling to modulate neuro-
inflammation and AD pathology in vivo has not been
yet completely elucidated. Recent data from our la-
boratory [24] have demonstrated that administration
for one month of a biomass preparation from Coriolus
versicolor was able to modulate redox-dependently cellular
stress response in rat. In view of the neuroinflammatory
nature of Alzheimer’s disease pathogenesis and taken into
account the therapeutic potential of mushroom nutritional
approaches, the present study was conducted in order to
gain insight into the possible neuroprotective role of H. eri-
naceus biomass preparation against the inflammatory
process and to evaluate the impact of this intervention on
cellular stress response mechanism operating in rat brain.
Methods
Chemicals
All reagents were from Merck (Germany) and of the
highest grade available. Hericium erinaceus powder con-
taining both mycelium and primordia (young fruit body)
was supplied by Mycology Research Laboratories Ltd.
(United Kingdom).
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H. erinaceus biomass preparation
H. erinaceus is found almost worldwide; however, its
bioactivity varies depending on the habitat in which it
grows. To eliminate these variations in the present study
an established H. erinaceus strain was used which demon-
strates rapid and aggressive colonization. Our H. erinaceus
powder containing both mycelium and primordia (young
fruit body) was supplied by Mycology Research Laborator-
ies Ltd. This mushroom, cultivated into a biomass, is
grown on a sterilized (autoclaved) substrate. The produc-
tion process involves the inoculation of sterile organic
edible grain with spawn from the mother culture. The
fungus is thus allowed to colonize completely in an envir-
onment where the growth medium is aseptically kept. At
the correct stage of development, corresponding to the
maximum bioavailability the living biomass is aseptically
air-dried, granulated, tested microbiologically and reduced
in powder. In comparison to H. erinaceus extracts, biomass
has the advantage of preserving all nutraceutical potential
which is usually reduced with extracts or concentrates,
including lyophilisation, and thus the activity of the
product corresponds with the source mushroom, while
being further intensified by utilizing the entire myce-
lium. The H. erinaceus biomass powder containing
mycelium and primordia of the respective mushroom
was used for experiments.
Animals
The study was carried out using male Sprague-Dawley rats
(200 to 230 g; Harlan, Nossan, Italy). Food and water were
available ad libitum. The study was approved by the
University of Messina Review Board for the care of
animals. Animal care was in compliance with Italian regu-
lations on the protection of animals used for experimental
and other scientific purposes (DM116192) as well as
with the relevant European Economic Community
(EEC) regulations (OJ of EC L 358/1 12/18/1986).
Experimental groups and treatments
Animals were randomly allocated into the following groups:
Group 1: Sham + Veh = vehicle solution (saline) was
daily administered o.s. for 3 month (N = 10);
Group 2: Sham +H. erinaceus = same as the Sham +
Veh group, but H. erinaceus powder (200 mg/kg body
weight, soluble in saline o.s.) was administered daily by
stomach gavage for the full experiment duration of 3
month (N = 10).
At the proper time points, animals were killed, brains
quickly removed and dissected into the cerebral cortex,
hippocampus, striatum and cerebellum, according to a
standardized procedure, in a cold anatomical chamber
and following a protocol that allows a maximum of 50 s
time-variability for each sample across animals. SN was
dissected from the deepest part of the interpeduncolar
fossa. Samples from different rat brain areas, total brain,
and from liver and kidney were homogenized for 2 min
in 0.05 mol/L Tris–HCl buffer, pH 7.4 (1:9).
Sampling and lymphocyte purification
Blood was collected through cardiac puncture and
added to tubes containing EDTA. Aliquots (2 ml)
were utilized for lymphocytes purification, which was
accomplished by using the Ficoll Paque System
following the procedure provided by the manufacturer
(GEHealthcare, Piscataway, NJ, USA).
Western blot analysis
Inducible heat shock protein 70 (Hsp-70), heme
oxygenase-1 (HO-1) and thioredoxin (Trx) protein levels
were estimated by Western blot analysis which was accom-
plished as previously described [25]. Plasma samples were
processed as such, while the isolated lymphocyte pellet as
well as dissected brain regions brain were homogenized
and centrifuged at 10,000 × g for 10 min. The supernatant
was then used for analysis after determination of protein
content. Proteins extracted for each sample, at equal
concentration (50 μg) were boiled for 3 min in sample buf-
fer (containing 40 mM Tris–HCl pH7.4, 2.5 % SDS, 5 % 2-
mercaptoethanol, 5 % glycerol, 0.025 mg/ml of bromophe-
nol blue) and then separated on a polyacrylamide mini gels
precasting 4–20 % (codNB10420 NuSept Ltd Australia).
Separated proteins were transferred onto nitrocellulose
membrane (BIO-RAD, Hercules, CA,USA) in transfer
buffer containing (0.05 % SDS, 25 mM Tris, 192 mM
glycine and 20 % v/v methanol). The transfer of the
proteins on the nitrocellulose membrane was con-
firmed by staining with Ponceau Red which was then
removed by three washes in PBS (phosphate buffered
saline) for 5 min each. Membranes were then incu-
bated for 1 h at room temperature in 20 mM Tris
pH 7.4, 150 mM NaCl and Tween 20 (TBS-T) con-
taining 2 % milk powder and incubated with appropri-
ate primary anti-HSP-72, anti- HO-1, and anti-Trx
polyclonal antibodies (Santa Cruz Biotech. Inc.), overnight
at 4 °C in TBS-T. The same membrane was incubated
with a goat polyclonal antibody anti-beta-actin (SC 1615
Santa Cruz Biotech.Inc., Santa Cruz, CA, USA, dilution
1:1000) to verify that the concentration of protein loaded
in the gel was the same in each sample. Excess unbound
antibodies were removed by three washes are with TBS-T
for 5 min. After incubation with primary antibody, the
membranes were washed three times for 5 min. in TBS-T
and then incubated for 1 h at room temperature with the
secondary polyclonal antibody conjugated with horserad-
ish peroxidase (dilution1:500). The membranes were then
washed three times with TBS-T for 5 min. Finally, the
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membranes were incubated for 3 min with Super Signal
chemiluminiscence detection system kit (Cod34080 Pierce
Chemical Co, Rockford, IL, USA) to display the specific
protein bands for each antibody. The immunoreactive
bands were quantified by capturing the luminescence sig-
nal emitted from the membranes with the Gel Logic 2200
PRO (Bioscience) and analyzed with Molecular Imaging
software for the complete analysis of regions of interest
for measuring expression ratios. The molecular weight
of proteins analyzed was determined using a standard
curve prepared with protein molecular weight.
Quantification of LXA4
LXA4 was analyzed using ELISA kit (CEB452Ge
Cloud-Clone Corp). The assay was performed following
the instructions of the manufacturer and measured by a
microplate reader, by reading at 450 nm. For this assay,
aliquots of plasma or tissues homogenates were used. Tis-
sue samples after rinsed in to remove excess blood thor-
oughly and weighed before homogenization, were
homogenized in ice-cold PBS (0.01 M, pH 7.2). The result-
ing suspension was sonicated and then centrifuged for
5 min at 5000 × g at 4 °C, and supernatants collected. Ali-
quots of standard, blank, plasma or tissue homogenates
containing equal amounts of proteins were brought to a
final volume of 50 μL and added into the appropriate
wells, followed by addition of 50 μL of detection reagent
A to each well. The plate was shaken gently before incuba-
tion for 1 h at 37 °C. The solution was aspirated and the
wells were washed 3 times. The remaining liquid was re-
moved completely by snapping the plate onto absorbent
paper. 100 μL of detection reagent B were then added to
each well followed by incubation for 30 min at 37 °C. After
repeated washing (5 times), 90 μL of substrate solution
was added to each well followed by incubation for 25 min
at 37 °C. Finally, 50 μL of stop solution was added to each
well, before measurement through reading at 450 nm.
Statistical analysis
All results obtained were expressed in mean ± SEM. The
data was analyzed by ANOVA to compare the different
groups and considered significant with a p < 0.05. Each
experiment was carried out in triplicate and repeated
twice.
Results
Regional distribution of LXA4 expression in rat brain after
treatment with H. erinaceus
Expression of LXA4, in control animals and after
administration of H. erinaceus biomass preparation,
was investigated in different brain regions of rats, as well
as in plasma and peripheral tissues, such as liver and
kidney. Administration of H. erinaceus for 3 month at the
oral daily dose of 200 mg/Kg induced an increase in the
protein level of LXA4 in all brain regions examined. As
shown in Fig. 1, highest levels of Hericium-dependent
increase of LXA4 protein expression were observed in
cortex, hippocampus, as well as in total brain, followed
with a statistically significant difference by substantia
nigra, striatum, and cerebellum.
Mushroom-induced increase of LXA4 in peripheral tissues
In the group of animals receiving chronic administration
of H. erinaceus, compared to untreated controls, brain
changes in LXA4 protein were associated with a signifi-
cant (p < 0.05) increase in the plasma and in lymphocytes
(Fig. 2a), as well as in peripheral organs, such as liver and
kidney, as illustrated in Fig. 2b.
Fig. 1 Regional distribution of Lipoxin A4 in rat brain. LXA4 protein levels in different brain regions and in total brain of control or H. erinaceus-fed rats.
Values are expressed as mean ± SEM of three independent analyses on 10 animals per group. CX: cortex; Hp: Hippocampus; Cb: cerebellum; TB: Total
Brain. H. erinaceus, given orally at the dose of 200 mg/Kg for 3 month. *P < 0.05 vs control
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Modulation of HO-1, Hsp70 and Thioredoxin protein
expression in rat brain after mushroom supplementation
As reported in Fig. 3a and b, mushroom supplementation
with H. erinaceus biomass preparation, resulted in up-
regulation of brain cellular stress response proteins HO-1,
and the inducible isoform of Hsp70. A representative
Western blot, obtained probing total brain tissue hom-
ogenate with an antibody specific for the inducible isoform
of heme oxygenase protein, is also shown (Fig. 3a).
Western blot analysis of the inducible heat shock proteins
70 (Hsp72) revealed a significant increase in the brain of
animals receiving H. erinaceus compared to control group.
In the same figure a representative blot is reported
(Fig. 3b). Figure 3c reports results from analysis of Trx
protein expression in total brain of animals receiving H.
erinaceus, as compared to controls. As shown, Trx protein
increases significantly after Hericium supplementation.
These results were also confirmed when measuring HO-1,
Hsp70 and Trx protein expression in different brain
regions of animals supplemented with H. erinaceus, as
compared to the control group (Fig. 4a-c). Figure 4a shows
a significant increase of HO-1 protein levels induced by
this nutritional mushroom in the cortex and in the
hippocampus, whereas this increase was not statistically
significant vs controls in the cerebellum. In the same
figure a representative Western blot, obtained probing the
different brain regions for HO-1 is reported (Fig. 4a).
Figure 4b shows increased Hsp70 protein expression
after H. erinaceus administration, which was significant,
compared to control animals, in the cortex, hippocam-
pus and cerebellum. In the same figure a representative
Western blot, obtained probing the different brain
regions for inducible isoform of Hsp70 is reported
(Fig. 4b). Consistent with HO-1 and Hsp70 data, analysis
of thioredoxin protein revealed that H. erinaceus bio-
mass supplementation upregulated this protein levels in
the brain regions of cortex, hippocampus and cerebel-
lum (Fig. 4c), which was statistically significant in all
brain regions examined (P < 0.05 vs control).
We then investigated whether administration of H. eri-
naceus would have affected systemic as well as peripheral
stress response. As illustrated in Fig. 5a a significant induc-
tion of HO-1 protein was observed in the plasma, lympho-
cytes and, respectively, liver and kidney of H. erinaceus fed
rats, as compared to untreated rat group. Representative
blots are reported in the same figure. Figure 5b shows a
parallel increase in Hsp70 protein expression, which was
found in plasma, lymphocytes and liver, but not in the
kidney of H. erinaceus fed animals. Consistent to the
notion that mushroom biomass supplementation modu-
lates stress responsive vitagenes we also found an increased
protein expression of the redox sensitive Trx in lympho-
cyte of H. erinaceus fed rat, which was significantly higher
respect to basal expression of this redox protein measured
in control, untreated animals (Fig. 6). A representative
Western blot, obtained probing total brain tissue
homogenate with an antibody specific for the Trx
protein is shown in the same figure.
Discussion
AD has gained widespread attention because of its high
economic costs, which have reached $400 billion per year
in the USA alone, as well as the social costs, which are
more difficult to quantify [26]. AD-related pathological
markers include a progressive death of neurons in specific
areas with an accumulation of intracellular neurofibrillary
tangles (NFTs) and extracellular depositions of amyloid
plaques (APs). NFTs are composed of the misfolded
hyperphosphorylated microtubule-associated protein
Tau (MAPT or Tau), whereas APs are extracellular
deposits of misfolded and aggregated amyloid-beta
peptides (Aβ) [27, 28]. Because both NFTs and APs
are persistently found in areas with severe neuronal
Fig. 2 a Lipoxin A4 in rat blood. LXA4 levels in plasma and in
lymphocytes from rats fed H. erinaceus biomass preparation as
compared to control group. Data are expressed as mean ± SEM
of 10 animals per group. *P < 0.05 vs controls. b Lipoxin A4
in Liver and Kidney. LXA4 levels in liver and kidney from rats fed H.
erinaceus biomass preparation as compared to control group. Data are
expressed as mean ± SEM of 10 animals per group. *P< 0.05 vs controls
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death, these proteins were considered to be the main cause
of neuronal loss and the emergence of dementia, which is
a crucial symptom of AD; however, numerous drug trials
based on these proteins have failed to provide a useful AD
therapy [28]. A post-mortem study demonstrated that the
misfolded protein accumulation is a shared pattern in
many neurodegenerative diseases, including AD [25], con-
curring to the conclusion that accumulation of misfolded
proteins is a prominent potential cause of neurodegenera-
tion in AD [29]. Recently, the involvement of neuroinflam-
mation and microglial activation in the pathogenesis of AD
has been emphasized by compelling evidence from basic
and clinical research studies indicating that inflammation
induced by Aβ is intimately associated with the develop-
ment of AD neuropathology [19]. Relevant to the central
role of neuroinflammation in AD pathgenesis, are recent
advances in knowledge of the mechanisms of inflammatory
resolution, identifying lipoxins as attractive therapeutic
tools to treat diseases in which inflammation is involved
[22]. LXA4 is generated via the lipoxygenase pathway
during cell-cell interactions in inflammatory conditions,
whereas aspirin-triggered LXA4 (ATL), a molecule that
displays the same anti-inflammatory activities as the
native lipoxins, is generated after the acetylation of
cyclooxygenase-2 and is more resistant to metabolic
inactivation [23]. Lipoxins potentiate inflammatory
resolution by means of potent agonistic actions at the
G-protein coupled receptor, termed LXA4 receptor
(ALX/FPR2). Activation of ALX by LXA4 reduces many
endogenous processes, such as neutrophil and eosinophil
recruitment and activation, leukocyte migration, NF-kB
translocation, and chemokine and cytokine production
[22]. Likewise, evidence shows that LXA4 signaling primes
Fig. 3 a Inducible heme oxygenase in Total Brain. HO-1 protein levels
in the brain of rats fed H. erinaceus biomass preparation as compared to
control group. Total brain homogenates from control and mushroom
supplemented rats were assayed for HO-1 expression by Western blot.
The bar graph shows densitometric values, expressed as mean standard
error of mean of 3 independent analyses. P < 0.05 vs control. In
the representative immunoblot shown, β-actin has been used as
loading control. D.U., densitometric units. b Inducible Heat shock
protein 70 in Total brain. Hsp70 protein levels in the brain of
rats fed H. erinaceus biomass preparation as compared to control
group. Total brain homogenates from control and mushroom
supplemented rats were assayed for Hsp70 expression by Western blot.
The bar graph shows densitometric values, expressed as mean standard
error of mean of 3 independent analyses. P < 0.05 vs control. In
the representative immunoblot shown, β-actin has been used as
loading control. D.U., densitometric units. c Thioredoxin in Total
brain. Trx protein levels in the brain of rats fed H. erinaceus biomass
preparation as compared to control group. Total brain homogenates
from control and mushroom supplemented rats were assayed for Trx
expression by Western blot. The bar graph shows densitometric values,
expressed as mean standard error of mean of 3 independent analyses.
P < 0.05 vs control. In the representative immunoblot shown, β-actin
has been used as loading control. D.U., densitometric units
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macrophages for chemotaxis and enhances phagocytosis
of microorganisms and apoptotic cells. In the nervous
system, LXA4 protects neurons against experimental
stroke and Aβ42 toxicity by modulating inflammation. In
addition, lipoxins inhibit inflammatory pain processing
through their actions on astrocytic activation in the spinal
cord [30, 31]. However, the ability of LXA4 signaling to
modulate neuroinflammation and AD pathology in vivo
has not been yet completely elucidated.
Mushrooms provide a great potential as a polypharma-
ceutic drug because of the complexity of their chemical
contents and different varieties of bioactivities. If available
evidence suggests anti-oxidants, anti-tumor, antivirus,
anti-cancer, anti-inflammatory, immune modulating, anti-
microbial, and anti-diabetic activities from mushrooms
[32], however, contrarily to plant herbal medicines, which
are widely explored and relatively more advanced, the
brain and cognition health effects of mushrooms are in
the early stages of research. Here, by extending previous
finding on nutritional approaches to neuroinflammation,
we provide experimental evidence that administration of
H. erinaceus for 3 month to rats results in up regulation
of vitagenes, in particular Hsp70, HO-1 and Trx, an
effect associated with increased synthesis of LXA4 in
different brain regions of rat. This latter, an endogenous
eicosanoid, is emerging as an important resolvin, a class of
compounds endowed with the capability to promote
resolution of inflammation, therefore suggesting that
nutritional modulation with H. erinaceus, through redox-
dependent vitagene network might activate endogenous
Fig. 4 a Regional distribution of HO-1 in rat brain. HO-1 protein levels
in different brain regions of rats fed H. erinaceus biomass preparation
as compared to control group. Brain region homogenates from control
and mushroom supplemented rats were assayed for HO-1 expression
by Western blot. The bar graph shows densitometric values, expressed
as mean standard error of mean of 3 independent analyses. P < 0.05
vs control. In the representative immunoblot shown, β-actin has been
used as loading control. D.U., densitometric units. CX: cortex; Hp:
Hippocampus; Cb: cerebellum. b Regional distribution of Hsp70
in rat brain. Inducible Hsp70 protein levels in different brain regions of
rats fed H. erinaceus biomass preparation as compared to control group.
Brain region homogenates from control and mushroom supplemented
rats were assayed for Hsp70 expression by Western blot. The bar graph
shows densitometric values, expressed as mean standard error of mean
of 3 independent analyses. P < 0.05 vs control. In the representative
immunoblot shown, β-actin has been used as loading control. D.U.,
densitometric units. CX: cortex; Hp: Hippocampus; Cb: cerebellum.
c Regional distribution of thioredoxin in rat brain. Trx protein levels in
different brain regions of rats fed H. erinaceus biomass preparation as
compared to control group. Brain region homogenates from control
and mushroom supplemented rats were assayed for Trx expression by
Western blot. The bar graph shows densitometric values, expressed as
mean standard error of mean of 3 independent analyses. P < 0.05 vs
control. In the representative immunoblot shown, β-actin has been
used as loading control. D.U., densitometric units. CX: cortex; Hp:
Hippocampus; Cb: cerebellum
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“braking signal” processes impacting the inflammatory
process. We also provide evidence of neuroprotective
action of H. erinaceus when administered orally to rat.
Expression of LXA4, measured in different brain regions
after oral administration of a biomass H. erinaceus
preparation for 3 month increased significantly in all
brain regions examined, as compared to control group
of animals, particularly in cortex and cerebellum, followed
by substantia Nigra, striatum and cerebellum. LXA4 up-
regulation was associated with an increased content of
redox sensitive proteins involved in cellular stress response,
such as Hsp72, HO-1 and Trx. We show that SN exhibited
lower LXA4 content respect to other brain regions exam-
ined, both in control and mushroom stimulated animals.
This finding is relevant to AD and PD pathogenesis,
particularly to theories connecting aging and neuronal
degeneration with oxidative damage. SN neurons are de-
pleted during physiological aging and even more so in all
neurodegenerative processes associated with Parkinsonian
symptoms. [33–37]. In addition, we demonstrate that H.
erinaceus treatment resulted in a significant increase of
LXA4 in most of the brain regions examined and
modulated expression of cytoprotective proteins, such as
HO-1, Hsp70 and Trx. Our results are consistent with
recent evidence obtained in mice, showing neuroprotection
by H. erinaceus on Ab25–35 peptide-induced cognitive
dysfunction [38, 39]. In this study the powder of H. erina-
ceus was mixed with a normal powdered diet and the
Ab25–35 peptide was administered by intracerebroventric-
ular injection. The results revealed that H. erinaceus
prevented impairments of spatial short-term and visual
recognition memory induced by Ab25–35 in mice.
Furthermore, human trials with H. erinaceum derivatives
also have showed promising results in patients with
dementia based on Revised Hasegawa Dementia Scale
(HDS-R) [40].
Our results indicating that nutritional modulation of
critical proteins involved in brain stress tolerance can
be achieved via supplementation with a well character-
ized strain of H. erinaceus are relevant to those theories
connecting proteome control quality failure with age-
associated neurodegenerative diseases. Consistent to
this notion, in AD pathology, the accumulation of APs
composed of Aβ aggregates and neurofibrillary tangles
NFTs composed of misfolded Tau proteins, accumulation
of these proteins as consequence of faulty protein quality
control mechanisms, is associated with a deficit in those
mechanisms participating to induction of cytoprotective
proteins (Hsps) or, more in general, involved in the
cellular pathways of stress tolerance. It is conceivable that
in these conditions administration of H. erinaceus mush-
room, which increases the redox potential associated with
induction of vitagenes, may help vulnerable neurons to
resist to proteotoxic insults and hence to apoptotic neuro-
degeneration. This is furtherly corroborated by the finding
indicating that restoration of normal proteostasis is crucial
for neuronal survival [41].
The molecular chaperone Hsp70 protects cells from
injury by binding damaged proteins under stressful
situations. Members of the 70 kDa-heat shock protein fam-
ily (Hsp70s) are, in their function as molecular chaperones,
Fig. 5 a Inducible heme oxygenase-1 in peripheral tissues. HO-1 protein
levels in liver, lymphocyte, kidney and plasma from rats fed H. erinaceus
biomass preparation as compared to control group. Samples from
control and mushroom supplemented rats were assayed for HO-1
expression by Western blot. Bar graph shows the values expressed
as mean standard error of mean of 3 independent analyses. P < 0.05
vs control. In the representative immunoblot shown, β-actin has been
used as loading control. D.U., densitometric units. b. Inducible heat
shock protein 70 in peripheral tissues. Inducible Hsp 70 protein levels in
liver, lymphocyte, kidney and plasma from rats fed H. erinaceus biomass
preparation as compared to control group. Samples from control and
mushroom supplemented rats were assayed for Hsp70 expression by
Western blot. Bar graph shows the values expressed as mean standard
error of mean of 3 independent analyses. P< 0.05 vs control. In the
representative immunoblot shown, β-actin has been used as loading
control. D.U., densitometric units
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involved in folding of newly synthesized proteins and
refolding of damaged or misfolded proteins, as well as in
assembly and disassembly of protein complexes. All human
Hsp70s have highly conserved domain structures [42].
They consist of an N-terminal ATPase domain, a middle
region and an N-terminal peptide binding domain. How-
ever, they differ in expression patterns, cellular localization
and function. There are Hsp70’s specifically located in the
endoplasmatic reticulum (Grp78, also known as BiP) and
in the mitochondria (Grp75, also known as mortalin).
However, the members which are mainly located in the
cytosol and nucleus are the heat shock cognate protein 70
(Hsc70) and the heat shock protein 70 (Hsp70). Cellular
stress often leads to protein unfolding and, therefore, to
increased protein hydrophobicity, which may result in the
formation of toxic protein aggregates [42]. As recently
demonstrated, Hsp70 expression is induced under the mild
oxidative stress conditions, when oxidative damage to
proteins leads to their unfolding [43], and the heat shock
response is activated driving increases in the expression of
molecular chaperones, which reaches about two-fold the
baseline levels [43]. Although HSP’s can refold mildly
disordered proteins, it is clear that HSP’s are not able to
repair covalently-modified oxidized proteins or to reverse
oxidative protein modifications, which results in increased
protein hydrophobicity, as triggering signal for the activa-
tion of a highly regulated and rapid series of events, called
the ‘heat shock response’ (HSR). Heat shock transcription
factor 1 (HSF1) is bound to a complex of heat shock
proteins (Hsps), such as Hsp70 and Hsp90, during non-
stressed conditions and, therefore, kept in an inactive state.
When Hsps recognize hydrophobic patches of damaged
and unfolded proteins, the Hsps dissolve from the complex
with HSF1 in response to cellular stress. This event is
followed by HSF1 trimer formation, which further leads to
the activation and translocation of the transcription factor
into the nucleus, where the trimer binds to the heat shock
gene promoters, the so called heat shock elements (HSEs).
This leads to the fast expression of Hsps [44]. Moreover,
the heat shock genes do not contain introns, which further
accelerates their expression. An unfolded protein that
binds to Hsp70 may be either refolded into its native non-
toxic conformation and then released, or may stay bound
by Hsp70 to protect non-damaged molecules. Since most
oxidative protein modifications are not repairable due to
their covalent nature, the majority of oxidized proteins are
degraded by the proteasomal system.
Conclusions
Our finding can open up new neuroprotective strategies,
as interventions aiming at inducing the vitagene defense
system mechanism, including Hsps, HO-1, thioredoxin
and lipoxin A4, can represent a therapeutic target to
minimize the deleterious consequences associated to
oxidative stress, such as in brain aging and neurodegen-
erative disorders.
Abbreviations
AD, Alzheimer’s disease; APs, amyloid plaques; ATL, aspirin-triggered LXA4; Aβ,
amyloid-beta peptides; EEC, European Economic Community; ER, endoplamic
reticulum; H. erinaceus, Hericium. erinaceus; HDS-R, Revised Hasegawa Dementia
Fig. 6 Inducible Thioredoxin in peripheral tissues. Trx protein levels in lymphocyte from rats fed H. erinaceus biomass preparation as compared to
control group. Samples from control and mushroom supplemented rats were assayed for Trx expression by Western blot. Bar graph shows values
expressed as mean standard error of mean of 3 independent analyses. P < 0.05 vs control. The representative immunoblot shows Trx and β-actin,
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